Practice Guideline
doi: 10.1093/annonc/mdr371.
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Affiliations
- PMID: 21908498
- DOI: 10.1093/annonc/mdr371
Item in Clipboard
Practice Guideline
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol.
2011 Sep.
Free article
No abstract available
Comment in
-
Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease.Ann Oncol. 2013 Feb;24(2):555-557. doi: 10.1093/annonc/mds637. Ann Oncol. 2013. PMID: 23341481 No abstract available.
-
Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al.Ann Oncol. 2013 Feb;24(2):557. doi: 10.1093/annonc/mds639. Ann Oncol. 2013. PMID: 23341482 No abstract available.
Similar articles
-
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2011 Sep;22 Suppl 6:vi25-30. doi: 10.1093/annonc/mdr372. Ann Oncol. 2011. PMID: 21908499 No abstract available.
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2010 May;21 Suppl 5:v9-14. doi: 10.1093/annonc/mdq159. Ann Oncol. 2010. PMID: 20555111 No abstract available.
-
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298. Ann Oncol. 2015. PMID: 26314782 No abstract available.
-
Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.Ann Oncol. 2009 May;20 Suppl 4:10-4. doi: 10.1093/annonc/mdp114. Ann Oncol. 2009. PMID: 19454421 Review. No abstract available.
-
Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.Ann Oncol. 2009 May;20 Suppl 4:15-8. doi: 10.1093/annonc/mdp115. Ann Oncol. 2009. PMID: 19454439 Review. No abstract available.
Cited by
-
The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26. Breast Cancer Res Treat. 2013. PMID: 23801158 Free PMC article. Clinical Trial.
-
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.Int J Environ Res Public Health. 2020 Mar 20;17(6):2078. doi: 10.3390/ijerph17062078. Int J Environ Res Public Health. 2020. PMID: 32245065 Free PMC article. Review.
-
The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Cancer Res Treat. 2015 Apr;47(2):208-14. doi: 10.4143/crt.2013.223. Epub 2014 Sep 11. Cancer Res Treat. 2015. PMID: 25381828 Free PMC article.
-
Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.EJC Suppl. 2013 Sep;11(2):3-22. doi: 10.1016/j.ejcsup.2013.07.029. EJC Suppl. 2013. PMID: 26217109 Free PMC article. Review. No abstract available.
-
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Springerplus. 2013 Dec;2(1):111. doi: 10.1186/2193-1801-2-111. Epub 2013 Mar 14. Springerplus. 2013. PMID: 23560250 Free PMC article.
